We are pleased to announce that Acellmed was among 151 innovative medical startups from Poland and the CEE region, presented in the “Top Disruptors in Healthcare” Report. The results of the Report were announced on June 6 this year during the AI & MEDTECH CEE conference. This report aims to present innovative medical startups, their…


On May 12 – 13, 2023, the 5th International Conference “Innovations in Ophthalmology” was held in Katowice. During the Conference, Acellmed together with researchers from the Silesian Park of Medical Technology Kardio-Med Silesia presented a poster entitled “An innovative method of producing a hydrogel dressing for autologous limbal cell transplantation in the treatment of limbal…


We are pleased to inform you that Acellmed and its corneal project have been noticed in #HuaweiStartupChallenge3, organized by @Huawei Polska and @Startup Academy. After successfully passing the first two stages of the competition, we are among 20 finalists – the best Polish startups (selected out of 168!)…

Our aim:

Acellmed is a start-up founded in 2019 as a response to regional and global market demand for implementing innovative pharmaceutical and biotechnology solutions. We are focused on developing medicinal products that provide optimal efficiency and safety. We have access to modern research and scientific background. We work with ambitious scientists and operate on the basis of a modern and refined business model. Our goal is to bring to market innovative and effective solutions in the field of pharmacy and medical biotechnology – especially solutions based on microRNA technology, stem cells and liposome drug carriers (nanotechnology). Acellmed addresses its offer to leading representatives of Big Pharma, R&D units and biotechnology companies from Poland and abroad.

The therapeutic preparation for corneal reconstruction using 3D bioprinting technology

The innovative treatment for personalized liposome-based therapy of acute myeloid leukemia, acute myeloblastic leukemia using small inhibitory RNAs

Stem cells (iPSCs) and corneal stem cells

The therapy for use in the treatment of infections caused by SARS-CoV-2 virus

Commercial research

One of the principal reasons to suspend ongoing research on new therapies is their cardiotoxicity. Regulations require that novel, and promising therapeutic molecules shall be subjected to the rigoristic toxicity tests using traditional methods in vitro and referential animal models. Those tests, however, do not reflect the reaction of human organism on drugs fully; also, they do not allow on detection of many potentially cardiotoxic substances. Direct application of drugs onto human cardiomyocytes, on the one hand, limits the use of lab animals; on the other – it creates a unique opportunity to select and test proper medications correcting particular cardiomyocytes defects. Directly-applied drugs are, therefore, the base of personalized medicine.


Moreover, Acellmed is developing a technology of “the heart-on-the chip,” based on the use of miniaturized micro-circulation systems which will allow on investigating the interaction between different heart cell types, and in the future – also of other organs.

Production line of iPSC and cardiomyocytes

In its research, Acellmed uses human peripheral blood cells (leucocytes), which effectively reprograms into iPSC; afterward, with high efficiency differentiates them into heart cells – cardiomyocytes. Hence we create iPSC bank cells from patients suffering from heart diseases (e.g., genetic primary and secondary cardiomyopathy) and healthy individuals.

Preparation in the field of regenerative medicine, in the form of a treatment using corneal limbus stem cells together with a transparent fibrin scaffold used to perform the procedure of corneal reconstruction for patients with lesions of various etiologies. The application of the preparation assumes autologous transplantation of cells taken from an individual patient and multiplied under laboratory conditions, which will then be applied to a biodegradable fibrin scaffold prepared in 3D technology.

As a part of current strategic activities related to the development of an innovative offer, Acellmed is focused on the development of a unique solution being an original nanotherapeutic with no analogue product on the world market so far, that would be effective against SARS-CoV-2 infection and inhibition of COVID-19 disease progression. To date, no similar approach has been found for the formula of an antiviral drug dedicated to the SARS-CoV-2 coronavirus. This furmula may prove to be as effective as or superior to mixtures of human or humanized monoclonal antibodies. The drug significantly reduces the mutational variability of human ACE2, while an approach that includes peptides with a sequence identical to fragments of the ACE2 protein provides no future resistance to the drug.

The actions will be conducted on the basis of microRNAs used in oncology therapy – which is currently a global trend in the field of oncology treatment. The aim will be to create a new unique nanomolecular product – based on RNA inhibitor drugs directed specifically to leukemic cells (blasts) characterized by the presence of specific markers. Depending on the characteristics of each type of acute myeloid leukemia (AML), it will be possible to use one or a mixture of preparations used in monotherapy or combined therapy with reduced doses of cytostatics or other drugs inhibiting the progression of the disease.

Our customers


  • Biotechnology, pharmaceutical and cosmetics


  • Scientists interested in research on IPSC and cells differentiated from iPSC


  • Health care providers / health care institutions

Our offer


  • Complete line of iPSC and cardiomyocytes
  • Conducting complete of generating iPSC and differentiated cel upon the commission of potential researchers interested in thier application

Research services

  • Research on the safety and effectiveness of potential drugs: comprehensive studies on the toxicity of selected substances – potential oncological drugs
  • Tests on drug efficacy in correcting cardiomyocytes defects, caused by functional disorder (as a result of mutations or undergoing oncological therapy)

Research on the safety and effectiveness of potenial drugs:

  • We offer the industry and health care institutions the toxicity studies, including tests on potential cardiotoxicity of the substances suspected to be an environmental threat

Our offer will enable the scientists and companies researching new drugs, on selecting safer substances, reducing unnecessary costs of preclinical trials; it may accelerate the process of introducing new drugs into the market.


    On the basis of Article 13 (1) and (2) of Regulation (EU) 2016/679 of the European Parliament and of the Council of 27.4.2016. (hereinafter: RODO) we inform you that:

    1. The administrator of your personal data is ACELLMED sp. z o. o., 10C M. Curie-Skłodowskiej Street, 41-800 Zabrze, POLAND, KRS: 0000800438, NIP: 6482795879, REGON: 384176690.

    2. For information regarding your personal data please contact us at the following e-mail address:

    3. Your personal data will be processed for the purpose of contacting you, responding to your inquiry on the basis of expressed consent in accordance with Article. 6(1)(a) RODO.

    4. Your personal data will be forwarded to e-mail hosts, companies dealing with IT support, website hosts.

    5. Your personal data will not be transferred to third countries, that is countries outside the European Economic Area.

    6. Your personal data will be processed until withdrawal of consent.

    7. You have the right to access your data and the right to rectify, delete, limit processing and revoke consent at any time.

    8. Providing data is voluntary.

    9. You have the right to lodge a complaint to the President of the Data Protection Office (ul. Stawki 2, 00-193 Warsaw, POLAND), if you believe that the processing of your personal data violates the law.

    10. Your data will not be processed in the form of profiling and automated decisions will not be made on their basis.


    ACELLMED Sp. z o. o.
    St. M. Curie-Skłodowskiej 10c
    41-800 Zabrze